Methods and compositions associated with the granulocyte colony-stimulating factor receptor
Some embodiments include compositions and methods of using or identifying compounds that modulate the activity of the granulocyte colony-stimulating factor receptor (GCFR). Some embodiments include use of compounds to treat certain disorders, such as hematopoietic or neurological disorders.
1. A compound of Formula (IIb) having the following structure:
a tautomer thereof, or a pharmaceutically acceptable salt thereof, wherein
R 3 is selected from hydrogen, an optionally substituted C 1 -C 6 alkyl, an optionally substituted C 3 -C 8 cycloalkyl, an optionally substituted C 1 -C 6 heterocycle, an optionally substituted aryl, and an optionally substituted heteroaryl;
R 4 is selected from an optionally substituted C 1 -C 6 alkyl, an optionally substituted C 3 -C 8 cycloalkyl, an optionally substituted C 1 -C 6 heterocyclyl; and
R 9 is selected from hydrogen, an optionally substituted C 1 -C 6 alkyl, an optionally substituted C 3 -C 8 cycloalkyl, an optionally substituted C 1 -C 6 heterocyclyl, an optionally substituted heteroaryl, an optionally substituted arylalkyl, and an optionally substituted heteroarylalkyl.
2. The compound of claim 1 , wherein:
R 3 is selected from hydrogen, and an optionally substituted C 1 -C 3 alkyl;
R 4 is selected from an optionally substituted C 1 -C 6 alkyl, an optionally substituted C 3 -C 8 cycloalkyl; and
R 9 is selected from an optionally substituted C 1 -C 6 alkyl, an optionally substituted arylalkyl, an optionally substituted arylalkenyl, an optionally substituted arylalkynyl, and an optionally substituted heteroarylalkyl.
3. The compound of claim 2 , wherein:
R 3 is an optionally substituted C 1 -C 3 alkyl;
R 4 is an optionally substituted C 1 -C 4 alkyl; and
R 9 is selected from an optionally substituted C 1 -C 3 alkyl, an optionally substituted arylalkyl, an optionally substituted arylalkenyl, and an optionally substituted arylalkynyl.
4. The compound of claim 3 , wherein R 3 is a C 1 -C 4 alkyl.
5. The compound of claim 4 , wherein R 3 is methyl.
6. The compound of claim 3 , wherein R 4 is a C 1 -C 4 alkyl substituted with hydroxy, cyano, or phenyl.
7. The compound of claim 6 , wherein R 4 is a C 1 -C 4 alkyl substituted with hydroxy.
8. A pharmaceutical composition comprising the compound of claim 1 and a pharmaceutically acceptable excipient.